Can Screening Reduce Mortality from Ovarian Cancer?

Findings from massive U.K. trial show promise.

To determine whether screening is effective at reducing mortality from ovarian cancer, investigators in the U.K. randomized >200,000 postmenopausal women (age range, 50–74; mean age at baseline, 61) to no screening, annual transvaginal ultrasound screening (TVUS), or annual multimodal screening (MMS) with serum CA125 using the Risk of Ovarian Cancer Algorithm (ROCA), which takes into account temporal changes in CA125 levels. Women assessed as normal risk by ROCA criteria were advised to undergo repeat CA125 assessment in 1 year. Those assessed as intermediate risk were advised to repeat CA125 assessment in 3 months, and those assessed as high risk were advised to undergo TVUS in addition to repeat CA125 testing.

At a median follow-up of 11 y…

Reviewing Author

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Can Screening Reduce Mortality from Ovarian Cancer?

Topics

Reviewing Author